EQS-Adhoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital in-crease of up to 154,053 shares
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital
Increase
Marinomed Biotech AG: Publication of a report on the exclusion of
subscription rights for a possible second cash capital in-crease of up to
154,053 shares
27-Nov-2024 / 12:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Korneuburg, Austria, 27. November 2024 – As Marinomed Biotech AG (the
„Company“ or „Marinomed“) announced in its ad hoc announcement dated 18
September 2024 regarding the first cash capital increase of 154,053 new
shares (the „First Cash Capital Increase“), the Company is negotiating
with investors regarding a possible second cash capital increase, which
would be carried out in accordance with the authorisation to exclude the
subscription rights of existing shareholders (the „Second Capital
Increase“). Marinomed is currently continuing to discuss with several
investors such a Second Capital Increase, although no agreements or board
resolutions have yet been reached.
The Company’s Management Board has resolved today to publish a report on
the intended exclusion of subscription rights of existing shareholders for
a possible cash capital increase of up to EUR 154,053 by issuing up to
154,053 new no-par value bearer shares against cash contribution (the
„Report“). The Report on the exclusion of subscription rights is to be
published as soon as possible on the electronic announcement and
information platform of the Federal Government of Austria („EVI“).
With the publication of the Report, the Company’s Management Board ensures
that, in the event of a short-term financing requirement of the Company,
the Company’s Management Board is legally in a position to resolve on a
new cash capital increase from the authorised capital 2024 in accordance
with § 5 para (6) of the Company’s Articles of Association (the
„Authorised Capital 2024“) at short notice with the approval of the
Supervisory Board. The background to this is that a report on the planned
exclusion of subscription rights must be published at least two weeks
prior to the required Supervisory Board resolution. Against the background
of the cash ratio to be deposited in accordance with the adopted
restructuring plan, the Company is creating the prerequisite for being
able to raise necessary equity at short notice and not having to wait for
the two-week period to expire in this case.
The actual implementation of a possible Second Capital Increase remains
dependent on the outcome of negotiations with investors, the conclusion of
the respective transaction documents and the adoption of resolutions by
the Company’s Management Board and Supervisory Board. In addition, the
restructuring proceedings (still needed for a Second Capital Increase)
require the approval by the restructuring administrator.
+++ End of ad-hoc announcement +++
End of Inside Information
══════════════════════════════════════════════════════════════════════════
27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2039559
End of Announcement EQS News Service
2039559 27-Nov-2024 CET/CEST
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender